Health tech firm Indegene has fixed a price band of Rs 430-452 for its maiden public offer, which opens for public subscription on May 6. The company plans to raise around Rs 1,842 crore through the issue, which closes on May 8.
The company received a capital markets regulator nod in August last year. The IPO comprises fresh equity issue worth up to Rs 750 crore and offer for sale (OFS) of up to 2.93 crore equity shares by existing investors.
Under the OFS, Manish Gupta, Rajesh Bhaskaran Nair, Anita Nair, Carlyle, Brighton Park Capital, Nadathur Family Office among others will offload shares.
The funds raised through the fresh issue would be used to pay debt, fund capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, fund inorganic growth and general corporate purposes.
Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.
Also Read: JNK India IPO sails through on Day 2. Check subscription, GMP and other details
The company combines over two decades of healthcare domain expertise and our technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products.
The portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 2023, the company had 65 active clients whom we cater to from six operation hubs and 17 offices located across North America, Europe and Asia.
For the period ended December 2023, the company clocked revenue from operations of Rs 1,969 crore and posted a profit after tax of Rs 241 crore.
Kotak Mahindra Capital, Citigroup Global Markets India, J P Morgan India, Nomura Financial Advisory and Securities (India) are the book-running lead managers to the issue.
